No photo of Jonathan M Ducore

View Scopus Profile

Jonathan M Ducore, MD

Professor

  • 1642 Citations
  • 19 h-Index
1976 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Jonathan M Ducore is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

DNA Medicine & Life Sciences
Precursor Cell Lymphoblastic Leukemia-Lymphoma Medicine & Life Sciences
Hemophilia A Medicine & Life Sciences
DNA Damage Medicine & Life Sciences
Melphalan Medicine & Life Sciences
DNA Repair Medicine & Life Sciences
Theophylline Medicine & Life Sciences
Single-Stranded DNA Breaks Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1983 1990

RNA CHANGES BY L-PAM IN HUMAN CELLS

Ducore, J. M.

National Institutes of Health

8/1/86 → 8/31/90

Project: Research project

Melphalan
Phenylalanine
RNA
Poly A
Uridine

MECHANISM OF ACTION OF BIFUNCTIONAL ALKYLATING AGENTS

Ducore, J. M.

National Institutes of Health

7/1/83 → 6/30/86

Project: Research project

Alkylating Agents
DNA Damage
DNA
Platinum
Alkylation

Research Output 1976 2019

  • 1642 Citations
  • 19 h-Index
  • 67 Article
  • 5 Chapter
  • 2 Letter

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial

Santagostino, E., Lalezari, S., Reding, M. T., Ducore, J. M., Ng, H. J., Poulsen, L. H., Michaels, L. A. & Linardi, C. C. G., Nov 1 2019, In : Thrombosis research. 183, p. 13-19 7 p.

Research output: Contribution to journal › Article

Open Access
Factor VIII
Hemophilia A
Half-Life
Clinical Trials
Safety

A novel approach to immune tolerance induction in haemophilia A with factor VIII inhibitor

Thornburg, C. D. & Ducore, J. M., Jan 1 2018, (Accepted/In press) In : Haemophilia.

Research output: Contribution to journal › Article

Immune Tolerance
Factor VIII
Hemophilia A
10 Citations (Scopus)

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

Liesner, R. J., Abashidze, M., Aleinikova, O., Altisent, C., Belletrutti, M. J., Borel-Derlon, A., Carcao, M., Chambost, H., Chan, A. K. C., Dubey, L., Ducore, J. M., Fouzia, N. A., Gattens, M., Gruel, Y., Guillet, B., Kavardakova, N., El Khorassani, M., Klukowska, A., Lambert, T., Lohade, S. & 10 others, Sigaud, M., Turea, V., Wu, J. K. M., Vdovin, V., Pavlova, A., Jansen, M., Belyanskaya, L., Walter, O., Knaub, S. & Neufeld, E. J., Mar 1 2018, In : Haemophilia. 24, 2, p. 211-220 10 p.

Research output: Contribution to journal › Article

Hemophilia A
Safety
Incidence
Confidence Intervals
Hemorrhage
124 Citations (Scopus)

Hemophilia B gene therapy with a high-specific-activity factor IX variant

George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J. M., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., McGuinn, C. E., Ragni, M. V., Luk, A. Y., Hui, D., Wright, J. F., Chen, Y., Liu, Y., Wachtel, K., Winters, A., Tiefenbacher, S. & 8 others, Arruda, V. R., Van Der Loo, J. C. M., Zelenaia, O., Takefman, D., Carr, M. E., Couto, L. B., Anguela, X. M. & High, K. A., Dec 7 2017, In : New England Journal of Medicine. 377, 23, p. 2215-2227 13 p.

Research output: Contribution to journal › Article

Hemophilia B
Factor IX
Coagulants
Genetic Therapy
Hemorrhage
7 Citations (Scopus)

PERSEPT 1: A phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding

Wang, M., Lawrence, J. B., Quon, D. V., Ducore, J. M., Simpson, M. L., Boggio, L. N., Mitchell, I. S., Yuan, G., Alexander, W. A. & Schved, J. F., 2017, (Accepted/In press) In : Haemophilia.

Research output: Contribution to journal › Article

Hemophilia A
Hemorrhage
Hemophilia B
Hemostasis
Uncertainty